These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Liposomal chemotherapies.
    Author: Smart T.
    Journal: GMHC Treat Issues; 1995; 9(7/8):13. PubMed ID: 11362653.
    Abstract:
    Vestar has asked for a second time for Food and Drug Administration (FDA) approval of DaunoXome, a liposomal daunorubicin, for the treatment of patients with systemic Kaposi's Sarcoma (KS) based on results from a large phase III trial. Overall response rates were lower than expected in this trial, with only 23 percent responding to DaunoXome, and there were slightly more than expected cases of reported neutropenia. However, incidence of toxicity such as hair loss, fatigue, and neuropathy were significantly lower. One other liposomal anthracycline, Doxil, has also been recommended for approval. No trials as yet have been done to compare the two drugs' effectiveness, although quality-of-life issues make these drugs attractive candidates.
    [Abstract] [Full Text] [Related] [New Search]